Division of New Drug Development, R&D Center, Jeil Pharmaceutical Co., Ltd. 117-1, Keungok-Ri, Baekam-Myun, Cheoin-Gu, Yongin-City, Kyunggi-Do 449-861, Republic of Korea.
Bioorg Med Chem Lett. 2013 Jul 1;23(13):3983-7. doi: 10.1016/j.bmcl.2013.03.119. Epub 2013 Apr 4.
New potent glycogen synthase kinase-3 (GSK-3) inhibitors, 8-amino-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives, were designed by modeling, synthesized and evaluated in vitro. Compound 17c showed good potency in enzyme and cell-based assays (IC50=111 nM, EC50=1.78 μM). Moreover, it has demonstrated desirable water solubility, PK profile, and moderate brain penetration.
新型强效糖原合酶激酶-3(GSK-3)抑制剂 8-氨基-[1,2,4]三唑并[4,3-a]吡啶-3(2H)-酮衍生物通过建模设计、合成并进行了体外评估。化合物 17c 在酶和基于细胞的测定中表现出良好的活性(IC50=111 nM,EC50=1.78 μM)。此外,它还具有良好的水溶性、PK 特征和中等的脑穿透性。